Randomized, double-blind,placebo-controlled, phase III cross-over study evaluating the oralneurokinin-1antagonist aprepitant in combination with a 5HT3 receptorantagonist and dexamethasone in patients with germ cell tumors receiving5-day cisplatin combination chemotherapy regimens: a hosier oncologygroup study

查看全文 作　　者：Albany C1; Brames MJ; Fausel C; 出　　处：《J ClinOncol》索引2012年第30卷第32期,共0页